SLT Glaucoma Laser Introduced to U.S. Market; Device Reduces Intraocular Pressure (IOP) in Glaucoma Patients
Quantel Medical officials announced that Solutis, an SLT (selective laser trabeculoplasty) glaucoma laser, has been approved for clinical use by the U.S. Food and Drug Administration.
This approval by the FDA follows the expiration of a patent issued to Massachusetts General Hospital, which restricted Quantel Medical and several other laser manufacturers from marketing SLT within the United States. Quantel has been providing SLT technology to customers outside the United States since 2007.
SLT is an effective first-line and adjunct therapy option for reducing intraocular pressure (IOP) in glaucoma patients. The non-invasive procedure delivers targeted laser energy, inducing a regenerative response at the cellular level. Due to the laser energy's gentle application, the treatment is repeatable, as well as not associated with the ocular and systemic side effects or compliance issues commonly linked to glaucoma drugs.
In use since 2007, Quantel's Solutis laser offers several clinician-friendly features, facilitating easy integration into a hospital or clinical setting. The design is adaptable to a physician's current slit lamp, eliminating the need for dedicated space and lowering end-user cost. The compact design also allows for easy transport from room to room or office to office, and includes convenient storage accessories when not in use.
"This FDA market clearance of our SLT laser marks an important step in Quantel's strategy for the U.S. market," says Jean-Marc Gendre, CEO of Quantel Medical. "Solutis has proven to be an attractive laser solution worldwide, and we are proud to now offer this laser alongside our robust line of multispot and YAG lasers. Our laser product line is uniquely designed to create combination systems, allowing for multiple laser applications in a single configuration, meeting the specific needs of each ophthalmology practice."
Selective Laser Trabeculoplasty (SLT) is laser treatment for primary open angle glaucoma (POAG). POAG patients are diagnosed with elevated intraocular pressure due to the lack of functionality in the trabecular meshwork. The 532nm laser targets and is absorbed by melanin-rich cells to induce a healing response, restoring functionality of the trabecular meshwork, and reducing and maintaining IOP. SLT is characterized as a gentle laser therapy in comparison to ALT or administration of medication, and is now considered effective for first-line, adjunct, or secondary line of treatment. SLT has been available since 2001.